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Abstract: The curative potential of retroviral vectors for somatic gene therapy has been 
demonstrated  impressively  in  several  clinical  trials  leading  to  sustained  long-term 
correction of the underlying genetic defect. Preclinical studies and clinical monitoring of 
gene  modified  hematopoietic  stem  and  progenitor  cells  in  patients  have  shown  that 
biologically relevant vector induced side effects, ranging from in vitro immortalization to 
clonal dominance and oncogenesis in vivo, accompany therapeutic efficiency of integrating 
retroviral  gene  transfer  systems.  Most  importantly,  it  has  been  demonstrated  that  the 
genotoxic potential is not identical among all retroviral vector systems designed for clinical 
application.  Large  scale  viral  integration  site  determination  has  uncovered  significant 
differences in the target site selection of retrovirus subfamilies influencing the propensity 
for inducing genetic alterations in the host genome. In this review we will summarize 
recent insights gained on the mechanisms of insertional mutagenesis based on intrinsic 
target site selection of different retrovirus families. We will also discuss examples of side 
effects occurring in ongoing human gene therapy trials and future prospectives in the field. 
Keywords: retroviral vectors; retroviral integration; gene therapy; insertional mutagenesis; 
vector genotoxicity; Leukemia; common insertion sites 
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1. Introduction  
The defining feature of retroviral replication is the integration of the reverse transcribed viral DNA 
into the genome of the host cell [1,2]. Efficient integration of the viral DNA into the host genome is a 
hallmark of the retroviral life cycle making replication-incompetent retroviral vectors attractive gene 
transfer vehicles for stable ectopic expression of transgenes in target cells. The understanding of basic 
principles of the retroviral replication cycle has led to the development of replication incompetent 
retroviral vectors capable of a single integration event upon infection of target cells in the absence of 
superinfection [3–6]. Since their first description in the beginning of the 1980s, a variety of vector 
systems from the two different retroviral subfamilies—Orthoretrovirinae and Spumaretrovirinae—
have been developed, which are broadly applied in basic and clinical research as ectopic gene delivery  
vehicles  [7,8].  The  viral  integration  reaction  catalyzed  by  the  viral  integrase  protein  has  been 
extensively  analyzed  revealing  complex  interactions  with  cellular  host  proteins  regulating  nuclear 
import, chromatin tethering and integration into the host genome [9,10].  
Being  applied  in  >357  initiated  clinical  phase  I/II  gene  therapy  trials,  retroviral  based  vectors 
represent the second most commonly used gene delivery vehicles after adenoviral vectors [11]. Stable 
integration  into  the  host  genome  and  subsequent  long-term  ectopic  expression  of  therapeutic 
transgenes  underlines  the  potential  of  retroviral  gene  transfer  systems  for  correction  of  inherited 
diseases [12]. 
Gene therapy for inherited diseases has demonstrated that modification and retransplantation of 
gene corrected (stem) cells cures severe disorders. The success of these gene therapy trials has been 
accomplished  by  replacing  genetically  non-functional  genes  present  in  the  patients‘  cells  with 
retroviral vectors constitutively expressing the therapeutical gene after random integration into the host 
genome. Consequently, the retroviral integration sites (RIS) create unique genetic signatures which 
can be amplified and sequenced to follow the fate of individual retrovirally ‗molecular marked‘ cells 
and  their  clonal  progeny  in  the  respective  target  tissue  [13].  Development  of  technologies  for 
identification and sequencing of retroviral integration sites together with the publication of the human 
genome sequence have led to precise insights in the global integration pattern of different retrovirus 
subfamilies  [14–20].  These  integration  site  profiling  studies  uncovered  unexpected  virus  specific 
integration  preferences  most  likely  resulting  from  different  interactions  of  the  viral  integration 
machinery and host factors [21]. Comprehensive studies of retrovirally transduced cells and their fate 
in  vivo  by  large  scale  integration  site  analyses  of  preclinical  and  clinical  samples  have  provided 
evidence that the propensity for insertional mutagenesis is, at least in part, influenced by the non-
random integration site selection of retroviral vectors [22]. 
In this chapter we will focus on recent insights in the target site selection of retroviral vectors and 
the  molecular  mechanisms  underlying  retroviral  vector  induced  mutagenesis.  An  overview  of 
subsequent biological effects of insertional mutagenesis is given based on preclinical and clinical data. 
We will introduce recent advances in next generation sequencing technologies and their impact on 
future high-throughput integration site analyses, both for mutation and vector biosafety research, and 
highlight their potential for a comprehensive clinical monitoring of current and future stem cell gene 
therapy trials using retroviral based vectors.  
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2. Trafficking to the Nucleus and the Retroviral Integration Reaction 
Pioneering  studies  identifying  the  reverse  transcriptase  as  a  key  component  of  retroviruses 
responsible  for  the  conversion  of  the  viral  RNA  genome  into  viral  DNA  [23,24]  supported  the 
provirus/protovirus [25,26] hypotheses by Howard Temin and led to the discovery of integrated vector 
genomes  in  many  different  organisms  [27–32].  After  penetrating  the  cell  membrane,  the  viral 
nucleoprotein  core  particle  containing  two  copies  of  viral  genomic  RNA  is  delivered  into  the 
cytoplasm where uncoating of the viral capsid takes place and reverse transcription is initiated [9]. 
Except for spumaviruses, which seem to have a unique mechanism to reversely transcribe their RNA 
genome late in the replication cycle [33,34], all other retroviruses initiate reverse transcription directly 
after endocytosis at the cell membrane [35]. The newly synthesized viral DNA remains in a large 
nucleoprotein  complex  called  the  pre-integration  complex  (PIC)  and  is  associated  with  viral  and 
cellular  proteins  [36–38].  The  PIC  interacts  with  the  microtubule  (MT)  network  that  regulates 
intracellular trafficking to the nucleus [39–41]. Once at the nuclear membrane, gammaretrovirus based 
vectors such as MoMLV require the breakdown of the nuclear envelope during cell division to enter 
the nucleus [42]. In contrast, the PIC components of lentivirus based vectors [43] interact with the 
nuclear  pore  complexes  allowing  entry  across  the  intact  nuclear  envelope  [9].  Similar  to  yeast 
retrotransposons whose integration complexes interact with host proteins, interaction of the retroviral 
PIC with cellular proteins and their karyophilic properties support the tethering of the viral DNA 
genome to chromatin where the integration reaction is initiated [9,44]. 
The basic molecular mechanism of retroviral integration has been demonstrated in biochemical 
studies in vitro [45] and has been further elucidated by recent structural work [46,47]. The first steps in 
the integration reaction are catalyzed by the viral integrase and are initiated by the 3´-prime processing 
reaction  which  results  in  the  removal  of  two  nucleotides  from  each  3´-prime  end  of  the  viral  
DNA [45,48,49]. The exposed 3´-prime hydroxyl groups at each end of the viral DNA are joined to the 
target DNA and subsequent strand transfer reaction of a pair of processed viral DNA ends leads to a 
concerted insertion of the viral DNA into the host genome [45,48–50]. The sites of strand transfer on 
the two target  strands  are  separated by 4–5 base pairs. Repair of this integration intermediate by 
cellular components [51] results in a direct duplication of 4–5 base pairs flanking the integrated viral 
DNA [2]. Most DNA sequences can act as integration acceptor sites, however, recent large scale 
studies on the integration site consensus of retroviruses in vivo [15,52,53] and in vitro [46,47] have 
shown that the base composition at retroviral target sites is biased for preferences or avoidances of 
particular bases supporting physical effects of the primary sequence on chromatin and the integration 
reaction, respectively.  
2.1. Distribution of Retroviral Integration Sites in the Cellular Genome in vitro and in vivo 
Since the discovery that integration is an essential step in the replication cycle of retroviruses, 
attempts were made to isolate proviruses and map their genomic location [2]. From in vitro studies 
using the purified integrase and recombinant chromatin it was suggested that nucleosome positioning 
influences the integration reaction [54–57]. Early studies on integration targeting of MLV in cultured 
cells  proposed  that  integration  was  favored  near  DNaseI  hypersensitive  sites  or  transcribed  
regions  [58–61].  However,  due  to  the  low  number  of  individual  insertion  sites  analyzed  and  the Viruses 2011, 3                         
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formerly  unknown human  genome  sequence,  target  site  selection of retroviruses across the whole 
genome was considered to be random.  
The target site selection of retroviruses and retroviral vectors has gained novel scientific interest, 
since  severe  adverse  events  during  the  gene  therapy  trial  for  X-SCID  [62]  were  linked  to  the 
integration of the therapeutic MLV based vector in vicinity of the LMO2 proto-oncogene [63,64]. 
Activating insertional mutagenesis of LMO2 in combination with acquired somatic mutations was 
responsible for the development of leukemia in a minority of the treated patients [65,66] and raised 
serious concerns whether the risk for insertional side effects is dependent on the target site selection 
and similar across all retroviral based vector systems [22]. 
With the decoding of the human genome and the development of PCR methodologies for allowing 
the amplification and sequencing of the genomic junctions between viral and host DNA the exact 
genomic  location  of  a  potentially  unrestricted  number  of  viral  integrants  generated  by  the  acute 
infection  of  cultured  cells  with  retroviruses  or  retroviral  vectors  became  feasible.  Analyzing their 
position  in  the  human  genome  has  uncovered  virus  specific  integration  patterns  (Table  1) 
distinguishing most retroviral subfamilies from each other (Figure 1). The first large scale comparative 
analyses of integration target site selection in the human genome was performed with MLV and HIV-1 
based vectors in a human cell line using LM-PCR and subsequent sequencing of the vector cellular 
junctions [19]. Compelling data demonstrated that RIS from MLV and HIV-1 based vectors showed 
distinct differences in respect to annotated features of the human genome. MLV vectors revealed a 
significant clustering around the transcription start site (TSS) of RefSeq genes and in the proximity to 
CpG-islands whereas HIV-1 based vectors disfavored TSS and CpG islands, but showed preferences 
for integration inside transcribed regions of RefSeq genes [19]. The preference for the integration of 
HIV-1  inside  RefSeq  genes  was  previously  shown  in  a  human  lymphoid  cell  line  [20]  and  also 
detectable with other vector systems from the lentiviral family pointing to a conserved mechanism of 
target site selection of lentiviruses [16,67,68]. These insights indicate that a mechanism involving the 
viral integrase and cellular genes is responsible for tethering the integration complex into particular 
regions of the genome. However, the investigated integration pattern of avian sarcoma and leukemia 
virus (ASLV) and prototype foamy virus (PFV) based vectors in human cells showed a rather random 
like distribution in relation to genes TSS and CpG-islands indicating that integration site selection of 
these retroviral families is not influenced by particular chromosomal structures and occurs rather by 
chance  [14,15,18].  Based  on  changed  integration  patterns  of  HIV-1  hybrid  vectors  carrying  the 
integrase  gene  of  MLV  it  has  been  suggested  that  the  principal  viral  determinant  of  retroviral 
integration  specificity  is  the  viral  integrase  itself  [69].  The  interaction  of  the  HIV-1  integration 
complex  with  the  cellular  protein  LEDGF/p75  plays  a  critical  role  in  HIV-1  replication  [70,71], 
protecting the viral integrase from proteosomal degradation [72] and increasing the affinity of the 
integrase to chromatin [73,74]. The siRNA mediated down regulation of LEDGF/p75 has been shown 
to  influence  the  normal  target  site  selection  of  HIV-1  based  vectors  decreasing  its  propensity  to 
integrate into transcription units [75–78]. Very recently a comprehensive integration site analyses of 
HIV-1 based vectors in rodent eye and brain tissue revealed a decreasing preference for integration 
into transcription units correlating with a cell specific lowered expression level of LEDGF/p75 [79]. 
More intense investigations of different retroviruses and the functional analyses of cellular proteins 
interacting with their integration machinery will shed more light on the mechanism that retroviruses Viruses 2011, 3                         
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have evolved to maintain host cell genome integrity in accordance with virus specific replication and 
pathogenesis. The understanding of biochemical principles controlling the tethering of the retroviral 
integration complex to chromatin together with recent findings showing that such knowledge can be 
applied  to  redirect  the  integration  pattern  of  HIV-1  based  vectors  are  promising  for  the  future 
development of therapeutic vectors which are designed to integrate into potentially safer sites of the 
genome [80–83]. 
Table 1. Integration pattern of different retroviral vectors. 
Virus  Genes  TSS  CpG-Rich Islands  Reference 
HIV  +  −  −  [19,20] 
SIV  +  −  −  [67] 
MLV  ±  +  +  [18,19,67] 
ALV  ±  −  −  [17] 
ASLV  ±  −  −  [18] 
PFV  −  ±  ±  [14,15] 
EIAV  +  −  ±  [16,68] 
HTLV-1  ±  −  −  [84,85] 
(+) strong preference; (−) no preference; (±) weak preferences. 
The correlation of target site selection of HIV-1 based vectors to gene expression profiling data of 
virus  infected  cells  has  revealed  that  transcriptional  activity  of  chromatin  influences  the  genome 
accessibility of the retroviral integration complex [18,86]. Genes showing transcriptional activity have 
a  higher  propensity  to  be  targeted  by  the  HIV-1  integration  complex  [18].  Most  likely,  the 
transcriptional activity of chromosomal regions also plays a role in the expression of viral genes for 
wild-type  retroviruses  as  well  as  transgene  expression  from  retroviral  vectors.  Influences  on  the 
transgene expression level based on chromosomal regions have been demonstrated for HIV-1 based 
vectors with higher transgene expression from integrated vectors to be located on more active open 
chromatin  [87].  From  the  evolutionary  standpoint  and  pathogenesis  of  retroviral  families  it  is 
interesting  to  note that  ASV compared  to  HIV-1 seems  to  favor  integration  into more condensed 
chromatin in vitro similar to properties found at heterochromatin [88]; however, it remains elusive 
what  mechanism  controls  these  differences  and  if  such  differences  might  explain  the  different 
pathology of these retroviruses.  
Recently, a genome wide analysis of >4000 transcription factor binding sites (TFBS) in the vicinity 
of MLV integration sites identified TFBS as differential genomic determinants of retroviral target site 
selection in the human genome. Gamma-retroviral vectors integrate in genomic regions enriched in 
cell-type specific subsets of TFBS suggesting that interaction of transcription factors with the viral 
LTR enhancer may synergize with the integrase in tethering retroviral pre-integration complexes to 
transcriptionally  active  regulatory  regions  [89].  A  comparative  analysis  of  gamma-retroviral 
integration sites between infused gene corrected mature lymphocytes (peripheral blood lymphocytes, 
PBL) and single infusion of hematopoietic stem/progenitor cells (HSC) of patients from the adenosine 
deaminase-severe  combined  immunodeficiency  (ADA-SCID)  clinical  trial  have  revealed  that  the 
insertional profile of MLV based vectors is cell-specific according to the genetic/chromatin state of the Viruses 2011, 3                         
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target cell [90,91] indicating that retroviruses have developed different strategies to interact with the 
host chromatin which seem to influence integration site selection substantially [89,90].  
Figure  1.  Integration  site  selection  of  retroviral  based  vectors  in  the  cellular  genome.  
(A)  Analysis  of  individual  vectors  to  target  sites  upstream  and  downstream  of  the 
transcription start site (TSS) at a 2.5 kb window size relative to the random control, which 
was set arbitrarily to 1 show that murine leukemia virus (MLV) based vectors have the 
strongest preference to integrate in close proximity to TSS. Prototype foamy virus (PFV) 
based vectors integrate at a rate approximately three- to four-fold higher than the expected 
random  value,  while  HIV-based  vectors  avoid  these  regions;  (B)  The  preference  to 
integrate into transcribed regions of genes is strongest for HIV based vectors followed by 
MLV  vectors,  which  show  weaker  preferences,  while  PFV  vectors  do  not  show  any 
preferences for target site selection in genes. Their integration preference towards genes is 
similar to what would be expected if target site selection would be random; (C) Frequency 
of retroviral vectors to integrate in the vicinity of CpG islands matched to the random 
control, which was set arbitrarily to 1 is dramatically increased with MLV based vectors. 
HIV and PFV vectors do not show any strong preferences for integration near to CpG 
islands (modified from Nowrouzi et al. [11]). 
A. 
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Figure 1. Cont. 
B.
C.
 
To  what  degree  does  the  different  integration  pattern  of  retroviruses  and  their  vector  derivates 
influence the likelihood for insertional mutagenesis? It is generally recognized  that known preferences of 
gammaretroviral vectors to target regulatory regions of genes increase the risk for genetic alterations of 
neighboring genes [22,92]. In contrast, it has been shown that independent of the integration pattern also 
vector design and dose influence the likelihood of vector induced cellular transformation [93,94]. Virus 
specific transcriptional enhancers within the LTR have been identified as one of the major determinants 
of genotoxicity independent of retrovirus subtypes [93,94]. The deletion of enhancer/promoter elements 
within the retroviral LTR, termed self inactivating (SIN) LTR, significantly decrease the propensity to 
cellular transformation demo nstrated in an in vitro immortalization assay [95]. However, at the same time 
it was elegantly shown in a tumor prone mouse model [96] that there is a significant higher load needed 
with LV vectors containing gammaretroviral enhancer elements to trigger oncogenesis when compared to 
MLV-based vectors [93,97]. The authors suggest that the higher vector load required for oncogenesis by 
LV vectors is most likely explainable by a higher preference of MLV-vectors to integrate near cancer 
promoting genes pointing to a role of intrinsic viral integration patterns inducing genotoxicity. Initial 
studies  using  PFV-vectors  with  rather  random  like  integration  patterns  with  respect  to  genes  and 
regulatory regions of genes in a canine preclinical model have not resulted in any detectable insertional 
induced  side  effects  [98],  arguing  that  random  and  uniform  integration  is  safer  in  terms  of  genetic 
alterations of the host genome. 
Taken  together,  many  large  scale  integration  site  distribution studies  have  been  conducted  and 
contributed to a better understanding of factors which may influence integration site preferences of 
retroviral  vectors.  Potential  genetically  safer  vector  systems,  based  on  their  integration  target  site 
selection, have been evaluated by several groups showing that deletion of viral genotoxic elements and Viruses 2011, 3                         
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the use of physiological (cellular) promoters significantly reduce the risk for insertional mutagenesis in 
future gene therapy trials.  
2.2. Next Generation Sequencing and Unbiased Retrieval of Vector Integration Sites 
For characterization of proviral cellular junctions two fundamental PCR methods were developed: 
inverse  PCR  [99]  and  ligation-mediated  PCR  [100–102].  Although  further  development  in  these 
methodologies led to improvements in sensitivity, the invention of the linear amplification-mediated 
PCR (LAM-PCR) [103,104] enabled the characterization of integration sites at the single-cell level for 
the  first  time,  allowing  monitoring  of retrovirally  gene-modified  hematopoiesis  directly  in  limited 
amounts of peripheral blood leukocytes and bone marrow cells [105]. Combined with next generation 
sequencing platforms and strategies for saturated genomic access [106–108] LAM-PCR has proven to 
be highly efficient for retrieval of whole insertional inventories in clinical and preclinical samples 
[109] (Figure 2) and analyzing the clonality of the hematopoietic repopulation after transplantation in 
humans [66,110–114].  
Figure  2.  Analyzing clonal dynamics and insertional induced side effects by retroviral 
integration site analyzes and next generation sequencing. 
 
The principle of LAM-PCR has been described previously in detail [103]. The first step is the  
pre-amplification  of  the  vector-genome  junctions  by  a  linear  amplification  step  with  biotinylated 
primers hybridizing at one end of the integrated vector. The following steps are carried out on a 
semisolid streptavidin phase in order to capture DNA strands with an incorporated biotinylated vector 
primer. After double strand synthesis, a restriction digest, and the ligation of a linker cassette on the 
genomic end of the fragment, two exponential PCRs with nested arranged vector- and linker cassette Viruses 2011, 3                         
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primers are carried out in order to amplify the fragments consisting of linker cassette-, genomic-, and 
vector-sequence.  The  generated  fragments  are  sequenced  and  the  integration  loci  are  determined. 
Application of novel next-generation sequencing technologies for integration site analysis by several 
groups have led to a marked increase in the retrieval of integration site information. We have recently 
applied 454 pyroseqeuncing and annotation of restriction motives in the human genome to define the 
genomic accessibility to viral integration sites and developed a new modified protocol for unbiased 
retrieval  of  insertion  sites  based  on  the  non-restrictive  LAM-PCR  (nrLAM-PCR)  [106,107].  
The  nrLAM-PCR  allows  the  genome-wide  identification  of  retroviral  integration  sites  in  a  single 
reaction,  circumventing  the  detection  bias  accompanied  by  methods  dependent  on  restriction  
enzymes [106,107]. Multiplex barcoding [115] of samples together with downstream bioinformatical 
evaluation of up to 1 million 400 bp long reads in one sequencing run enables analyzing over hundred 
thousand RIS in multiple samples at the same time [107]. This is efficient to analyze whole insertional 
inventories of patients, clonal dynamics and integration patterns of any kind of integrating genetic 
elements in parallel. Most importantly, LAM-PCR or nrLAM-PCR combined with next generation 
sequencing platforms (i.e., 454, Solexa, ABI) allow a semi quantitative retrieval of insertion sites 
representing unique molecular identities of particular marked clones in a given sample, highly valuable 
to monitor clonal dynamics in hematopoeisis and many other biological systems [110,114,116–118]. 
Several commercial sequencing platforms are available, each having its advantages and disadvantages. 
The platforms from Solexa (Genome Analyzer) and Applied Biosystems (SOLID) generate very high 
numbers  of  sequence  reads,  but  are  limited  in  individual  sequence  length.  The  pyrosequencing 
platform from 454 Life Sciences (Titanium system; Roche Diagnostics) allows the generation of up to 
5 × 10
5 sequence reads of ~400 base pairs (bp) in length in a single sequencing run sufficient to 
chromosomal map amplicons with vector cellular junctions without using complicated algorithms to 
process short sequence reads.  
3. Side Effects in Clinical and Preclinical Gene Therapy Studies 
First  molecular  insights  in  the  oncogenic  potential  of  integrated  wild  type  retroviruses  were 
obtained from bursal lymphomas in chicken. The majority of the identified tumor cells contained a 
provirus integrated in the vicinity of the proto-oncogene c-myc that was overexpressed by the viral 
promoters/enhancers  [119–122].  These  genetic  alterations  caused  by  retroviruses,  termed  proviral 
insertional mutagenesis, have been identified in many types of retrovirus induced tumors [123,124]. 
Thereby,  a  variety  of  genes  could  be  identified  that  modulate  growth  and  differentiation  and 
significantly  contributed  to  tumor  formation.  Despite  these  insights  obtained  from  wild-type 
retroviruses and replication-competent retroviral vectors, the risk of insertional mutagenesis (Figure 3) 
and cellular transformation with replication-incompetent vectors specifically developed for clinical 
purposes was considered to be rather low [125]. 
However, after first cases of severe adverse events in a minority of patients in the X-SCID gene 
therapy trial were reported (see next chapter), the first malignant transformation that developed as a 
result  of  gene  transfer  using  replication-deficient  retroviral  vectors  designed  for  clinical  use  in  a 
murine model was observed in 2002 [126]. In a murine model system the serial transplantation of bone 
marrow cells marked with gammaretroviral vectors led to tumor development in secondary and tertiary Viruses 2011, 3                         
 
 
438 
recipients [126]. All secondary transplanted animals showed alterations in their hematopoiesis after 22 
weeks,  and  six  out  of  ten  animals  developed  acute  myeloid  leukemia.  Molecular  analyses  of  the 
malignant clone in respect to the RIS using LM-PCR revealed that in all developed tumors derived 
from  secondary  and  tertiary  recipients  an  insertion  in  the  Evi1  gene  locus  triggering  malignant 
transformation was detected [126]. Although it was shown that the promoter and enhancer elements in 
the proviral  LTR caused  an  overexpression of Evi1, a synergistic effect of the low-affinity nerve 
growth factor receptor (LNGFR) remains unclear [126]. In terms of clinical safety it is important to 
note that vector dose has an impact on leukemogenesis as shown in a murine study where Leukemia 
not only occurred due to the growth advantage of single clones but also correlated with high vector 
doses using MLV based vectors [127]. Soon after, gene marking studies in a non-human primate 
model provided evidence for clonal dominance due to an insertional effect of MLV based vectors in 
vicinity of the Mds1/Evi or Prdm16 gene. This insertional event led to a growth advantage compared 
to other marked cell clones without causing malignant transformation [128]. Since the majority of 
these cell clones contribute to long-term hematopoiesis, a higher engraftment or survival probability as 
a result of insertional mutagenesis was discussed [22,128]. Vector induced side effects with possible 
roles in hematopoietic activity have also been reported in a murine gene marking study in which 
proviral  integration  within  or  nearby  particular  cellular  genes  promoted  the  growth  of  single 
transduced cells and contributed to their clonal expansion in vivo [129]. The first retroviral vector 
induced acute myeloid leukemia in a non-human primate model was described after retroviral gene 
transfer in hematopoietic precursor cells. The treated animal died five years after gene therapy due to a 
myeloid sarcoma caused by two insertions in the Bcl2-A1 and Cdw91 genes. In this study the clone 
harboring these two insertions was both detectable in the blood where it became dominant one year 
after  transplantation  as  well  as  in  the  tumor,  strengthening  a  cooperative  functional  role  of  these 
insertions in tumor development [130].  
Human gene therapy using retroviral vectors is a specialized form of therapy that is mainly applied 
to patients for whom no therapeutic alternatives are available. Therefore, the benefit of gene therapy 
always has to be opposed to its potential risks. The field has suffered from a lot of initial hype without 
taking into account that any new kind of specialized therapy may also be accompanied by side effects. 
The  success  of  human  gene  therapy  for  hematopoietic  diseases  has  been  enabled  by  the  greater 
efficiency  in  performing  ex  vivo  transduction  of  human  CD34
+  cells  using  retroviral  vectors  and 
reinfusion of a high number (up to 10
8−10
9) of gene-corrected cells. In retrospect, it is now evident 
that improvement in effectiveness for curing otherwise challenging lethal diseases is accompanied by a 
higher risk of biologically relevant side effects of this type of gene therapy. Up until now most gene 
therapy trials in the hematopoietic system involve the use of first generation MLV derived retroviral 
vectors. Classical MLV based vectors carrying the full LTR are now based on their integration site 
selection and vector design considered to have a higher potential for genotoxic events as compared to 
lentiviral based vectors (see below). 
Monitoring the in vivo fate of gene corrected CD34
+ cells retransplanted into patients by high-
throughput integration site analysis in five independent clinical gene therapy studies have shown that 
distribution of gammeretroviral vectors in vivo is skewed. Apart from subtle effects, clonal dominance 
and  leukemogenesis  influencing  the  growth  and  differentiation  of  clones  when  inserted  near  to 
particular genes and loci have been reported in minority of treated patients [64–66,111-114,131]. We Viruses 2011, 3                         
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have recently described that in addition to overt carcinogenesis, even as a single vector copy, many 
insertion locations more subtly influence the biological fate of a cell clone in vivo [111,112,123]. With 
LAM-PCR technology specifically developed for this purpose, it has been identified that up to 40% of 
circulating cells carry insertions in a rather small set of frequently affected common insertion sites 
(CIS) [111,112]. Such CIS are almost always in the direct vicinity of known and novel genes likely to 
be  involved  in  cellular  growth,  survival  and  self-renewal  processes  of  immature  progenitor  and 
stem cells.  
Figure 3. Retroviral vectors may induce mutations in multiple ways by integration of the 
retrovirus in the host genome. (A, B) Mutagenic proviral insertions in most reported cases 
induce an activation of neighboring genes by enhancer elements present within the wildtype 
LTR. Such ―enhancer insertions‖ can induce gene activation from distances up to 100 kb.  
(C,  D)  In case of SIN-type retroviral vectors strong internal promoters driving transgene 
expression may induce deregulation of genes in close proximity similar to so-called ―promotor 
insertions‖  which  result  in  viral-host  gene-fusion  transcripts.  (E)  Genotoxic  side  effects 
resulting from retroviral integration sites leading to inactivation of cellular genes may be 
induced by viral insertion within a host gene leading to truncated non functional transcripts. 
(A)
(B)
(C)
(D)
(E)
 
 
In the gene therapy trial for X -SCID, two to six years after successful correction of the otherwise 
lethal disease the development of T -cell leukemia in five of 19 patients has been observed [ 65,66]. In 
four of these patients the leukemic clone  harbored a  vector  integration  in  the  LMO2 proto-oncogene 
inducing its overexpression. Together with acquired mutations these events have led to expansion of 
these clones and the development of leukemia [65,66]. Although under dispute, the combinatorial 
effect of the IL2RG transgene in the development of the lymphoproliferative disease in the X-SCID Viruses 2011, 3                         
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trial has been discussed [132,133] and recent work from Copeland and colleagues provides supportive 
evidence that IL2RG and LMO2 do cooperate in leukemia induction [134]. At the same time skewing 
of RIS was observed in the healthy patients causing subtle insertional effects without any signs of 
malignant transformation [111,112]. 
Evidence for vector induced effects influencing hematopoietic activity have been gained in the gene 
therapy for the correction of X-CGD [113,117]. Here, in two adult patients, retroviral gene therapy 
resulted  in  the  restoration  of  oxidative  antimicrobial  activity  in  phagocytes  after  gene  transfer. 
Integration  site  analysis  revealed  a  clonal  dominance  triggered  by  insertion  sites  in  the  genes  
MDS1-EVI1,  PRDM16  or  SETBP1  (Figure  4A),  resulting  in  an  expansion  of  gene  corrected 
myelopoiesis [113,117]. In the follow up of the clinical trial a substantial gene transfer in neutrophil 
cells had produced a high number of functional phagocytes, however, after the initial resolution of 
bacterial  and  fungal  infections,  both  subjects  showed  silencing  of  transgene  expression  due  to 
methylation of the viral promoter, and myelodysplasia with monosomy 7 as a result of insertional 
activation  of  ecotropic  viral  integration  site  1  (EVI1).  It  has  been  recently  suggested  that  the 
overexpression  of  Evi1  disrupts  normal  centrosome  duplication  leading  to  genomic  instability, 
monosomy 7 and clonal progression toward myelodysplasia [117].  
From these severe adverse events it is tempting to reason that the use of gammaretroviral vectors is 
per se oncogenic. However, given that severe events have occurred in a minority of treated patients in 
the X-SCID trial, the clinical follow up of the ADA-SCID [131] trial using the same vector backbone 
as in the X-SCID trial has up to now not been accompanied by any adverse events up to 8 years post 
therapy. This may indicate that the risk for vector induced side effects may also be dependent on the 
disease and the clinical protocol. We note that clear evidence for this discussion has not been reported 
so far. 
In the most recent gene therapy trial for Wiskott-Aldrich Syndrome (WAS) an MLV-based vector 
backbone expressing the WAS protein was used for transduction of autologous CD34
+ HSC which 
were  transfused  into  two  patients.  WAS  is  a  primary  immunodeficiency  disorder  associated  with 
thrombocytopenia, eczema and autoimmunity and is alternatively treatable with haploidentical BM 
transplantation [114]. Here, monitoring the clonal contribution of gene corrected cells to hematopoietic 
regeneration  three  years  post  transfusion  by  a  comprehensive  integration  site  analysis  using  next 
generation sequencing technologies has identified over 10,000 unique clones contributing to short- and 
long-term  hematopoieses.  This  genome-wide  insertion  site  analysis  demonstrated  that  vector 
integration targeted multiple genes controlling growth development and immunological responses in a 
persistently  polyclonal  hematopoiesis.  However,  many  of  the  previously  observed  CIS,  which 
occasionally triggered adverse events, were detectable in both subjects to a similar degree suggesting 
vector induced skewing similar to what was observed in previous gene therapy trials using the MLV 
backbones (Figure 4B, C). In fact, it was further shown that in sorted cell populations of the lymphoid 
or myeloid fraction lineage specific CIS could be identified, which in previous gene therapy trials had 
triggered either lymphoid or myeloid proliferation suggesting that insertional activation of these genes 
programs  cell  fate  in  the  hematopoietic  system  [114].  In  total,  9/10  patients  have  been  treated 
successfully in this trial. Very recently it has been reported that one patient has developed a T-cell 
leukemia similar to the patients in the X-SCID trial. Whether vector induced effects have played a role Viruses 2011, 3                         
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in this side effect is under current investigation but it is most likely that vector induced side effects 
similar to the side effects observed in the minority of X-SCID patients may play a role here.  
Figure 4. Retroviral integration into common insertion sites in clinical gene therapy trials. 
(A) Clustering of retroviral integration sites (RIS) within clones sharing integrations in 
MDS1-EVI1,  PRDM16  and  SETBP1  in  the  X-CGD  clinical  trial  identified  by  linear 
amplification-mediated PCR (LAM-PCR) (modified from Ott et al. [113]). (B) Clinical 
monitoring  of  retroviral  gene  corrected  hematopoietic  stem/progenitor  cells  (HSC)  by 
LAM-PCR and 454 sequencing in two patients from the WAS gene therapy trial over time 
reveal multiple clones sharing insertion sites into common integration sites located near 
genes  previously  known  to  induce  malignant  clonal  expansion.  For  measuring  clonal 
contribution to hematopoiesis over time at every time point analyzed, sequence counts for 
all RIS contributing to an individual common insertion sites (CIS) derived from PBL and 
BM  were  clustered  and  related  to  total  sequence  count  at  the  respective  time  point 
(modified from Boztug et al. [114]). 
(A) 
 
(B)               (C) 
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First proof that switching the integration pattern of the therapeutical retroviral vector improves 
genotoxic safety has been provided by the first LV-based gene therapy trial for the treatment of the 
cerebral form of X-chromosomal linked adrenoleukodystrophy (X-ALD), a demyelinating disease of 
the central nervous system caused by mutations in the ABCD1 gene [110]. Progress of X-ALD is 
treatable by haploidentical BM transplantation, but with patients where no matching donor is found 
gene therapy is a highly promising therapeutic option [135]. In 2006, two patients with no sibling BM 
donors were treated with HIV-1 based vectors, which show distinct differences in target site selection 
and  efficiency  in  transducing  quiescent  cells  compared  to  MLV-based  vectors.  Mobilized 
hematopoietic precursor cells were harvested from two seven year-old patients, transduced ex vivo 
with  lentiviral  SIN-vectors  encoding  the  ABCD1  transgene  and  reinfused  into  the  patients.  This 
treatment  proved  efficient  to  arrest  the  progression  of  the  disease  in  both  patients  through  the 
constitutive expression of the functional ABCD1 therapeutic transgene. More importantly, no signs of 
vector  induced  side  effects  have  been  reported  so  far  in  two  treated  patients  continuously  being 
monitored.  Up  to  now,  the  clonal  dynamics  of  transduced  and  reinfused  CD34
+  HSC  show 
transduction  of  multipotent  HSC  and  no  signs  of  enrichment  near  to  CIS  genes  previously  being 
identified as integration hot spots of MLV-based vectors in vivo [110]. The improved clinical safety of 
SIN-type LV-based vectors compared to classical MLV-based vectors has previously been proposed 
based on evidence gained in sensitive mouse models designed to measure genotoxic safety [93,136]. 
Deduced with murine genotoxicity assays, although at low rate, vector induced genetic alterations have 
also  been  reported  with  target  site  selection  of  LV-based  vectors  [93,94,137].  Such  insertional 
alterations in the regulation of the cellular genome by LV-vectors have recently been reported in the 
gene therapy trial for human β-thalassaemia [118]. Clinical benefit of lentiviral β-globin gene transfer 
has been achieved in an adult patient 33 months post treatment by clonal dominance initiated by vector 
induced  activation  of  the  HMGA2  gene.  This  particular  clonal  dominance  has  been  proposed  to 
accompany clinical efficacy for β-thalassaemia, a challenging hematopoietic disease, and the most 
common form of severe thalassaemia in southeast Asian countries and their diasporas [118].  
New Strategies for Vector Biosafety in Gene Therapy 
The risk of side effects in future gene therapy trials will be dependent on the choice of the most 
suitable  gene  transfer  vector  dependent  on  the  individual  disease  and  the  propensity  for  genomic 
alterations driven by vector design and integration pattern. The usage of SIN-type vectors with weak 
or tissue-specific promoters or non-integrating vector systems—if appropriate—are considered to be 
safer than classical MLV-vectors. The use of AAV- or Adenovirus-vectors predominantly persisting 
episomaly  in  post-mitotic  tissue  (i.e.,  retina,  brain,  muscle  or  liver)  are  promising  for  particular 
diseases [138]. However, insertional mutagenesis caused by rare but detectable integration events with 
AAV-vectors in the liver has also been reported [139,140] underlining the need for highly sensitive 
strategies  to  detect  such  rare  insertions  in  a  clinical  setting.  In  postmitotic  tissues,  dilution  of 
unintegrated  episomal  vector  forms  does  not  occur  thus  allowing  the  use  of  integrase  deficient 
lentiviral vector systems [141]. Mutations in the core domain of the viral integrase prevent integration, 
thereby reducing the risk of insertional mutagenesis. Recently, the long-term functional correction of Viruses 2011, 3                         
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retinal degeneration in a well-established rodent model for ocular gene therapy was reported under the 
use of an integrase-deficient HIV-1 vector without apparent side effects [142].  
Alternative modification of the viral integrase for targeted integration into desired potentially safe 
chromosomal regions [143], together with significant improvements in the efficiency of homologous 
recombination  or  gene  disruption  using  novel  Zinc-Finger-Nucleases  (ZFN)  will  in  future  define 
alternative  gene  delivery  approaches  [144].  Other  non-viral  integrating  vector  systems  based  on 
sleeping beauty or piggybac transposons have been identified to have a potentially safer integration 
pattern in vitro [145]. However, given that any integrating vector system by chance, if combined with 
genotoxic vector elements, may induce genetic alterations of the cellular genome also account for 
transposon based vectors which are also used to identify novel cancer genes in murine models [146].  
With significant improvements in the controlled genetic modification of particular loci in targeted 
integration approaches and a variety of vectors with alternative integration patterns available it becomes 
evident that the advance of highly sensitive technologies for a comprehensive genomic screening is 
required to monitor safety on a genetic level. Whole genome next generation sequencing technologies to 
evaluate genomic stability and strategies for an unbiased retrieval of integrated sites [106] and induced 
DNA double-strand breaks will be essential for dissecting the genetic specificity and safety of novel 
targeted  gene  editing  protocols.  In  this  context,  recent  pioneering  advances  in  the  field  of  cellular 
reprogramming and the availability of sources of induced pluripotent cells (iPS) [147–149] or lineage 
specific  progenitor  cells  [150–152]  generated  by  integrating  vector  systems  expressing  particular 
pluripotency  of  lineage  regulating  transcription  factors  have  made  prediagnostic  genomic  safety 
screening of hundreds of clones feasible for potential future cell based therapies [153]. New vector 
systems and the potential use of new induced clinical applicable cell sources will greatly benefit from 
vector biosafety models established in the gene therapy field [154,155]. 
During  the  last  years  several  in  vitro  and  in  vivo  systems  have  been  developed  assessing  the 
genotoxic  potential of  different integrating vectors. Transplantation of gammaretroviral transduced 
hematopoietic cells in mice with knocked-out Cdkn2a tumor suppressor gene leads to accelerated 
tumor  growth  in  case  a  cellular  proto-oncogene  is  virally  activated  [96,156].  Such  conducted 
insertional mutagenesis screens have resulted in the establishment of the most extensive database of 
murine  genes  with  oncogenic  potential,  the  so-called  mouse  ―Retrovirally  Tagged  Cancer  Gene 
Database‖ (RTCGD) [157]. Recently also sleeping beauty transposon systems have been applied in a 
similar manner [158,159]. Du and colleagues showed that identification of protooncogenes is feasible 
by retroviral gene transfer in cell culture. Transduction of murine bone marrow cells with replication 
deficient retroviruses expressing  marker genes resulted in immortalized cell lines, many of which 
contained integrations in the Mds1/Evi1 and Prdm16 genes [160,161]. Vector integration into the Evi1 
locus and overexpression of Evi1 appeared to be sufficient for a cell to be immortalized [161,162]. 
Modlich and colleagues adapted and improved this method so that the results could be analyzed in a 
quantitative manner [95]. 
The tumor prone mouse model in which the tumor suppressor gene Arf as well as the Il2rg gene had 
been knocked-out originally developed by Lund et al. was suitable to perform comparative tests on the 
genotoxic  potential  of  different  gene  transfer  vectors  [96,97]. Mice that had received hematopoietic 
precursor cell transplants transduced with gammaretroviral vectors developed tumors much more rapidly 
than  mice  that  had  received  cells  harboring  lentiviral  SIN-vectors  with  an  internal  human Viruses 2011, 3                         
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phosphoglycerate kinase (hPGK) promoter [97]. Later, it was demonstrated that gammaretroviral vectors 
with SIN-LTRs show a significant reduction in genotoxicity, but when combined with strong (viral) 
internal promoters still have the ability to induce leukemia in transplanted mice [93]. Given that in 
follow-up of the first LV-vector gene therapy trial for X-ALD no signs of clonal dominance or side 
effects have been observed up to the present it seems reasonable that such mouse models realistically 
modulate clinical safety of integrating vector systems. Insertion of insulator elements in the LTRs aims to 
reduce the influence of the integrated vector on the surrounding host genome and vice versa [163,164]. 
However, evidence for increased genotoxic safety with the use of insulators [165] needs to be further 
provided in common in vitro and in vivo models for vector safety assessments, especially after insertional 
mutagenesis mediated clonal dominance has been reported in the lentiviral β-thalassaemia gene therapy 
trial in which the cHS4 chromatin insulator was implanted in the LTR of the therapeutic vector [118]. 
Improvement  of  genotoxic  safety  using  alternative  and  modified  vector  systems  together  with 
progress  in  targeted  integration  approaches  and  new  cell  sorting  abilities  provide  a  tremendous 
potential for future gene and cell therapy with increased safety. This will further improve the treatment 
of patients with otherwise not curable and often lethal inherited diseases.  
4. Conclusion and Future Perspective 
Large scale genome wide investigations of retroviral target site selection have shown that different 
retroviral  subfamilies  have  developed  different  mechanisms  to  integrate  their  DNA  into  the  host 
genome. Such differences result in three main integration patterns with MLV based vectors showing 
strong preferences for regulatory regions, LV-based vectors integrating preferentially inside RefSeq 
genes and PFV as well as ASLV having close to random insertional preferences. Towards safe clinical 
application of retroviral vectors uncovered target site preferences have proven to play substantial roles 
in  the  likelihood  for  insertional  mutagenesis  and  cellular  transformation.  Knowledge  gained  from 
comprehensive  integration  site  analysis  of  gene  therapy  patients  and  preclinical animal models  to 
assess  genotoxic  safety  of  retroviral  vectors  are  currently  being  actively  transferred  into  the 
development  of  new  and  safer  clinical  protocols  for  the  treatment  of  hematological  and 
neurodegenerative  diseases.  The  vision  of  using  vectors  with  targeted  synthetic  integrases  and 
improving the frequency of homologous recombination with ZFN or Meganucleases in order to correct 
defective  genes  or  insert  therapeutic  genes  into  potentially  ―safe  harbors‖  is  rapidly  evolving  to 
become  clinically  feasible.  In the era  of whole genome sequencing projects aiming to understand 
progress of cancer and other diseases on a genetic level, the treatment of many new diseases in which 
the pathogenesis is dependent on a gene defect may become treatable with novel safe retroviral vectors 
imposing minimal genomic side effects for the patients.  
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